[Multiple-Hit myeloma].
作者信息
Fang Y, Hou J
机构信息
Department of Hematology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200127, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):620-622. doi: 10.3760/cma.j.issn.0253-2727.2019.07.020.
Abstract
摘要
相似文献
1
[Multiple-Hit myeloma].[多发性打击骨髓瘤]
Zhonghua Xue Ye Xue Za Zhi. 2019 Jul 14;40(7):620-622. doi: 10.3760/cma.j.issn.0253-2727.2019.07.020.
2
Recurrent involvement of heterochromatic regions in multiple myeloma-a multicolor FISH study.多发性骨髓瘤中异染色质区的反复累及——一项多色 FISH 研究。
Leuk Res. 2010 Aug;34(8):1002-6. doi: 10.1016/j.leukres.2009.10.027. Epub 2009 Dec 21.
3
Cytogenetics helps determine diagnosis and prognosis for multiple myeloma.细胞遗传学有助于确定多发性骨髓瘤的诊断和预后。
ONS Connect. 2012 Dec;27(12):18-9.
4
Cytogenetic abnormalities in multiple myeloma.
Hematol Oncol Clin North Am. 1999 Dec;13(6):1169-80, viii. doi: 10.1016/s0889-8588(05)70119-2.
5
[Cytogenetic study of multiple myeloma].[多发性骨髓瘤的细胞遗传学研究]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007 Feb;15(1):76-8.
6
[Multiple myeloma: chromosomal abnormalities, clinical features and prognosis].[多发性骨髓瘤：染色体异常、临床特征及预后]
Rinsho Ketsueki. 2013 Oct;54(10):1856-66.
7
Clinical impact of chromosomal aberrations in multiple myeloma.多发性骨髓瘤中染色体异常的临床影响。
J Intern Med. 2011 Feb;269(2):137-47. doi: 10.1111/j.1365-2796.2010.02324.x. Epub 2010 Dec 15.
8
Prognosis in multiple myeloma.多发性骨髓瘤的预后
Cancer Treat Res. 1999;99:155-70. doi: 10.1007/978-0-585-38571-6_6.
9
Multiple chromosomal abnormalities in fulminant anaplastic myeloma.暴发性间变性骨髓瘤中的多种染色体异常。
Clin Lab Haematol. 1999 Jun;21(3):207-10. doi: 10.1046/j.1365-2257.1999.00207.x.
10
CHROMOSOME ABNORMALITIES IN MULTIPLE MYELOMA.多发性骨髓瘤中的染色体异常
Acta Haematol. 1963 Nov;30:274-9. doi: 10.1159/000208134.
本文引用的文献
1
Multiple Myeloma: Current Advances and Future Directions.多发性骨髓瘤：当前进展与未来方向
Clin Lymphoma Myeloma Leuk. 2019 May;19(5):255-263. doi: 10.1016/j.clml.2019.03.025. Epub 2019 Apr 1.
2
Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial.来那度胺维持治疗与观察用于初诊多发性骨髓瘤患者（Myeloma XI）：一项多中心、开放标签、随机、3 期临床试验。
Lancet Oncol. 2019 Jan;20(1):57-73. doi: 10.1016/S1470-2045(18)30687-9. Epub 2018 Dec 14.
3
The genomic features associated with high-risk multiple myeloma.与高危多发性骨髓瘤相关的基因组特征。
Oncotarget. 2018 Oct 26;9(84):35478-35479. doi: 10.18632/oncotarget.26269.
4
Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.造血干细胞移植治疗多发性骨髓瘤的应用：梅奥多发性骨髓瘤分层与风险适应性治疗（mSMART）共识声明。
Bone Marrow Transplant. 2019 Mar;54(3):353-367. doi: 10.1038/s41409-018-0264-8. Epub 2018 Jul 9.
5
A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis.通过基因组分析鉴定的一组新诊断骨髓瘤的高危、双重打击群体。
Leukemia. 2019 Jan;33(1):159-170. doi: 10.1038/s41375-018-0196-8. Epub 2018 Jul 2.
6
Multiple Myeloma: Clinical Updates From the American Society of Hematology Annual Meeting, 2017.多发性骨髓瘤：2017 年美国血液学会年会的临床更新。
Clin Lymphoma Myeloma Leuk. 2018 May;18(5):321-334. doi: 10.1016/j.clml.2018.02.015. Epub 2018 Mar 1.
7
Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients.新诊断骨髓瘤的预后预测：1905 试验患者分子谱的荟萃分析。
Leukemia. 2018 Jan;32(1):102-110. doi: 10.1038/leu.2017.179. Epub 2017 Jun 6.
8
Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.来那度胺、硼替佐米与地塞米松联合移植治疗骨髓瘤
N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.
9
Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management.多发性骨髓瘤：2016年诊断、风险分层及管理的最新进展
Am J Hematol. 2016 Jul;91(7):719-34. doi: 10.1002/ajh.24402.
10
The 2016 revision of the World Health Organization classification of lymphoid neoplasms.《世界卫生组织淋巴组织肿瘤分类（2016年修订版）》
Blood. 2016 May 19;127(20):2375-90. doi: 10.1182/blood-2016-01-643569. Epub 2016 Mar 15.
Zotero 插件